Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	28.87	28.36	34.81	29.43	39.14
Short-Term Investments	489.7	696.93	388.78	275.52	369.11
Cash & Short-Term Investments	518.57	725.28	423.6	304.95	408.25
Cash Growth	-28.50%	71.22%	38.91%	-25.30%	109.98%
Accounts Receivable	2.02	0.7	2.63	0.35	0.17
Other Current Assets	14.08	21.18	5.47	12.39	2.42
Total Current Assets	534.66	747.16	431.69	317.69	410.84
Net Property, Plant & Equipment	7.77	8.24	6.64	7.75	6.52
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19
Other Long-Term Assets	13.36	9.75	0.11	0.1	0.1
Total Assets	582.98	792.34	465.63	352.74	444.65
Accounts Payable	1.18	3.27	3.49	3.34	1.23
Accrued Expenses	47.03	33.84	22.03	12.84	12
Current Portion of Long-Term Debt	1.23	0.94	3.99	0.99	1.55
Current Portion of Leases	1.55	1.45	1.61	1.45	1.75
Total Current Liabilities	50.99	39.5	31.13	18.61	16.53
Long-Term Leases	0.78	2.36	0.93	2.59	1.3
Other Long-Term Liabilities	4.04	3.47	4.4	5.33	7.35
Total Long-Term Liabilities	4.83	5.83	5.33	7.92	8.65
Total Liabilities	55.82	45.34	36.46	26.53	25.18
Common Stock	0.07	0.07	0.06	0.05	0.05
Additional Paid-in Capital	2,337	2,299	1,823	1,581	1,561
Accumulated Other Comprehensive Income	3.63	3.31	3.31	1.26	1.89
Retained Earnings	-1,814	-1,555	-1,397	-1,256	-1,144
Shareholders' Equity	527.17	747.01	429.17	326.2	419.48
Total Liabilities & Equity	582.98	792.34	465.63	352.74	444.65
Total Debt	3.57	4.76	6.53	5.02	4.6
Net Cash (Debt)	515.01	720.53	417.07	299.93	403.65
Net Cash Growth	-28.52%	72.76%	39.06%	-25.70%	115.20%
Net Cash Per Share	7.75	11.19	8.61	6.40	9.42
Book Value	527.17	747.01	429.17	326.2	419.48
Book Value Per Share	7.94	11.60	8.86	6.96	9.78
Tangible Book Value	499.98	719.82	401.98	299.01	392.29
Tangible Book Value Per Share	7.53	11.18	8.30	6.38	9.15

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q